GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update
03 août 2022 16h00 HE
|
GeoVax, Inc.
Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology Evaluation of Company’s Vaccine Platform Against Monkeypox Underway ATLANTA, GA, Aug. 03, 2022 (GLOBE NEWSWIRE) --...
GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization
28 juil. 2022 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, July 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases...
GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update
26 juil. 2022 09h00 HE
|
GeoVax, Inc.
Conference Call to be Held Wednesday, August 3, at 4:30 p.m. Eastern Time ATLANTA, GA, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development
13 juin 2022 09h00 HE
|
GeoVax, Inc.
Operational Resources Strengthened to Support Company Growth and Development Atlanta, GA, June 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax to Present at BIO International Convention 2022
07 juin 2022 09h00 HE
|
GeoVax, Inc.
Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin® Atlanta, GA, June 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc....
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
25 mai 2022 13h47 HE
|
GeoVax, Inc.
Atlanta, GA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China
24 mai 2022 09h00 HE
|
GeoVax, Inc.
Atlanta, GA, May 24, 2022 (GLOBE NEWSWIRE) -- IND-Enabling Studies Underway in the United States for MVA-VLP-MUC1 Vaccine Candidate via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Announces Upcoming Presentations at Scientific Conferences
04 mai 2022 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases...
GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update
27 avr. 2022 16h00 HE
|
GeoVax, Inc.
Company Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology ATLANTA, GA, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a...
GeoVax Announces Issuance of Malaria Vaccine Patent
26 avr. 2022 09h00 HE
|
GeoVax, Inc.
GeoVax’s Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs,...